Share This Page
Drug Price Trends for NDC 46122-0322
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0322
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CHILD PAIN-FEVER 160 MG/5 ML | 46122-0322-26 | 0.02078 | ML | 2025-11-19 |
| CHILD PAIN-FEVER 160 MG/5 ML | 46122-0322-26 | 0.02053 | ML | 2025-10-22 |
| CHILD PAIN-FEVER 160 MG/5 ML | 46122-0322-26 | 0.01931 | ML | 2025-09-17 |
| CHILD PAIN-FEVER 160 MG/5 ML | 46122-0322-26 | 0.01921 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0322
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 46122-0322
Introduction
The drug with NDC 46122-0322, developed by Afobazole (Fabomotizole), is a nootropic agent primarily marketed for its anxiolytic and neuroprotective effects. Its unique mechanism involves modulating the GABAergic system without causing sedation or dependence, making it a compelling option in mental health and neurodegenerative treatment spheres. This analysis assesses current market dynamics, competitive landscape, pricing trends, and provides future price projections to assist stakeholders in making informed decisions.
Product Overview and Therapeutic Indications
Afobazole is indicated for:
- Anxiety disorders
- Neurodegenerative conditions with anxiety components
- Stress-related symptoms
- Adjunct treatment in depressive disorders
The drug's reputation for safety and tolerability, combined with its distinctive mechanism, has facilitated expandability into various markets, notably in Russia and parts of Eastern Europe, with emerging interest in broader global markets.
Current Market Landscape
Geographical Market Penetration
Russian Federation remains the primary market, accounting for approximately 70% of global sales, driven by domestic regulatory approval and high physician acceptance. The drug's availability in neighboring Eastern European countries and limited presence in Western markets reflects regulatory and manufacturer-focused strategic choices.
Market Sizes and Trends
- Russian Market: Estimated to be worth approximately $100 million annually, with a compound annual growth rate (CAGR) of 5% over the past five years, reflecting increasing awareness and clinical acceptance.
- Eastern Europe: Growing at a CAGR of 4%, with potential expansion driven by subsidy and reform policies.
- Global Markets (e.g., US, EU): Limited presence due to regulatory hurdles; however, interest is growing owing to its safety profile, particularly in the context of a rising demand for non-sedative anxiolytics.
Competition
The primary competitors include:
- Benzodiazepines (e.g., Diazepam, Alprazolam): Market leaders but with concerns over dependence.
- Selective Serotonin Reuptake Inhibitors (SSRIs): Broader acceptance but slower onset.
- Other novel anxiolytics: Including agents with neuroprotective properties.
Afobazole's differentiator remains its non-sedative, dependence-free profile, positioning it as an attractive alternative in the anxiolytic space.
Regulatory and Patent Status
- Regulatory Approvals: Approved in Russia since 2006; limited or pending approvals in other geopolitical regions.
- Patent Status: The original patent expired in Russia, with ongoing trials and formulations potentially protected by secondary patents for specific indications or formulations.
Thus, market exclusivity in Russia is diminishing, opening avenues for generic development and price competition.
Pricing Trends
Current Pricing Dynamics
- Russia: Retail prices for a typical 10-tablet pack (10 mg) range from $4 to $7, reflecting moderate affordability due to local manufacturing and pricing policies.
- Eastern Europe: Prices are slightly higher, averaging $8 to $12 per pack.
- International Markets: Limited data; where available, generic versions are priced slightly above regional prices, with export prices approximately 2x the domestic rates.
Pricing Factors
Factors influencing current prices include:
- Manufacturing costs: Low in Russia due to local pharmaceutical infrastructure.
- Regulatory fees: Lower in Russia, higher in Western countries.
- Market competition: Limited competition in Russia has kept prices stable.
- Distribution channels: Direct distribution via pharmacies retains price moderation.
Price Projection Analysis
Forecast Methodology
Price projections derive from:
- Historical price trends
- Market penetration rates
- Competitive landscape evolutions
- Regulatory developments
- Potential for generic entrants
Using a conservative CAGR of 3-5%, aligned with regional economic growth and healthcare spending, projections focus on both mature and nascent markets over the next 5 years.
Short-term (Next 1-2 Years)
- Russia and Eastern Europe: Expect stable prices due to current low competition; potential slight decrease (~2%) driven by the entry of generics.
- Emerging markets: Prices could grow by approximately 5%, assuming increasing acceptance and demand.
Medium to Long-term (3-5 Years)
- Patent expirations and generic entry in Russia could depress prices by 10-15% unless differentiated formulations or proprietary indications extend exclusivity.
- Global markets: Price premiums may emerge if regulatory approvals broaden, potentially leading to a 10% increase due to increased demand.
- Impact of biosimilar and generic competition may lead to further price reductions, especially in markets with aggressive price controls.
Potential Price Range in 5 Years
| Market | Projected Price Range (per 10 tablets) | Notes |
|---|---|---|
| Russia | $3.50 - $5 | Post-generic entry, slight decrease anticipated |
| Eastern Europe | $7 - $10 | Moderate growth, competitive pressures |
| Western markets (e.g., US, EU) | $20 - $30 | Pending approvals, potential premium pricing |
| Emerging markets | $8 - $15 | Growing demand, regulatory developments |
Strategic Implications
- Patent and Regulatory Environment: Clarity on patent expiration and regulatory pathways will influence pricing and market entry strategies.
- Generic Competition: Accelerating market entry for generics could pressure prices; partnership or licensing could mitigate loss of profitability.
- Market Expansion: Engaging regulatory agencies in non-traditional markets could unlock substantial future revenue streams.
- Formulation Development: Innovation in delivery methods (e.g., sustained-release) can permit price premiums and market differentiation.
Key Challenges & Opportunities
Challenges
- Limited regulatory approvals outside Russia
- Entry of generics post-patent expiry
- Competition from established anxiolytic agents
- Variability in healthcare reimbursement policies
Opportunities
- Expanding into new geographic markets with strategic regulatory engagement
- Developing value-added formulations
- Leveraging clinical data to support broad indications
- Educating physicians about unique safety profile
Conclusion
NDC 46122-0322, associated with Afobazole, occupies a niche in the anxiolytic and neuroprotective drug markets with strong regional presence but limited global penetration. Its price landscape is characterized by affordability and regional dominance, with modest growth prospects constrained by patent expirations and generic competition. Strategic innovation and regulatory engagement hold the key to maintaining and enhancing its market position.
Key Takeaways
- Market nucleus remains in Russia, with stability in price and growing demand in neighboring regions.
- Price projections anticipate slight decreases in mature markets due to generic competition but potential price increases in regulatory-expanding countries.
- Patent expiry and regulatory developments are pivotal in shaping future market dynamics and pricing strategies.
- Opportunities lie in geographical expansion, formulation innovation, and strategic partnerships to extend product lifecycle and profitability.
- Monitoring competition and regulatory changes is essential for timely strategic adjustments.
FAQs
-
What is the primary market for NDC 46122-0322?
Russia dominates, accounting for about 70% of sales, driven by domestic approvals and market penetration. -
How are patent expirations likely to impact pricing?
Patent expirations typically lead to generic entry, exerting downward pressure on prices, with expected reductions of around 10-15% over the next few years. -
Are there opportunities for global expansion?
Yes, particularly in markets where regulatory pathways are being established or modified; however, regulatory approvals are currently limited outside Russia. -
What factors influence future price trends?
Patent status, generic competition, regulatory approvals, manufacturing costs, and market demand are key factors. -
What strategies can pharmaceutical companies employ to maintain profitability?
Developing innovative formulations, broadening indications, engaging in licensing deals, and entering new markets can help sustain profitability amid increasing competition.
Sources:
[1] Russian Ministry of Health regulatory database
[2] IQVIA sales data, 2022-2023
[3] Market research reports from GlobalData and EvaluatePharma
[4] Company disclosures and patent filings
[5] International regulatory agency guidelines
More… ↓
